The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma
The Clinical Respiratory Journal · 2024
DOI: 10.1111/crj.13772 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Haijun Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First People's Hospital of Lianyungang, Lianyungang, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Biomarkers, Tumor, Immunoglobulins, Lung Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation for Youth of China, Jiangsu Province "333 Project" Research Projects, National Natural Science Foundation of China.
Abstract (Originalsprache)
Sialic acid‐binding immunoglobulin‐like lectin‐15 (Siglec‐15) has been identified as an immune suppressor and a promising candidate for immunotherapy of cancer management. However, the association between Siglec‐15 expression and clinicopathological features of lung adenocarcinoma (LUAD), especially the prognostic role, is not fully elucidated. In this present study, a serial of bioinformatics analyses in both tissue and cell levels were conducted to provide an overview of Siglec‐15 expression. Real‐time quantitative PCR (qPCR) test, western blotting assay, and immunohistochemistry (IHC) analyses were conducted to evaluate the expression of Siglec‐15 in LUAD. Survival analysis and Kaplan–Meier curve were employed to describe the prognostic parameters of LUAD. The results of bioinformatics analyses demonstrated the up‐regulation of Siglec‐15 expression in LUAD. The data of qPCR, western blotting, and IHC analyses further proved that the expression of Siglec‐15 in LUAD tissues was significantly increased than that in noncancerous tissues. Moreover, the expression level of Siglec‐15 protein in LUAD was substantially associated with TNM stage. LUAD cases with up‐regulated Siglec‐15 expression, positive N status, and advance TNM stage suffered a critical unfavorable prognosis. In conclusion, Siglec‐15 could be identified as a novel prognostic biomarker in LUAD and targeting Siglec‐15 may provide a promising strategy for LUAD immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First People's Hospital of Lianyungang, Lianyungang, China.
- The First Affiliated Hospital of Kangda College of Nanjing Medical University/The First People's Hospital of Lianyungang, Lianyungang, China.
- The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People's Hospital of Lianyungang, Lianyungang, China.
- Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang, Lianyungang, China.
- Department of Oncology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Central Laboratory, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Yuan Mao
Förderung
- National Natural Science Foundation for Youth of China
- Jiangsu Province "333 Project" Research Projects
- National Natural Science Foundation of China
- General Project of Jiangsu Provincial Commission of Health and Family Planning
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Zitieren
APA
Sun, H., Du, Q., Xu, Y., Rao, C., Xu, L., Yang, J., Mao, Y., & Wang, L. (2024). The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13772
Vancouver
Sun H, Du Q, Xu Y, Rao C, Xu L, Yang J, et al. The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.13772
BibTeX
@article{Sun2024,
author = {Sun, Haijun and Du, Qilong and Xu, Yuyu and Rao, Cheng and Xu, Li and Yang, Junrong and Mao, Yuan and Wang, Lin},
title = {The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma},
journal = {The Clinical Respiratory Journal},
year = {2024},
doi = {10.1111/crj.13772}
}
EUVIMED